Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

Nature Clinical Practice Oncology volume 4, pages 394–395 (2007)Cite this article

boxed-textAttal M et al. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289–3294

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fritz E and Ludwig H (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3,948 patients. Ann Oncol 11: 1427–1436

    Article  CAS  Google Scholar 

  2. Barlogie B et al. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24: 929–936

    Article  CAS  Google Scholar 

  3. Berenson JR et al. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99: 3163–3168

    Article  CAS  Google Scholar 

  4. Richardson PG et al. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458–3464

    Article  CAS  Google Scholar 

  5. Berenson JR et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–493

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chief of Division of Hematologic Neoplasia at DFCI and the Kraft Family Professor of Medicine at HMS, NC Munshi is the Associate Director of the Jerome Lipper Multiple Myeloma Center (JLMMC) at the Dana-Farber Cancer Institute (DFCI), Physician at Boston VA Healthcare System and Associate Professor of Medicine at Harvard Medical School (HMS), CS Mitsiades is Instructor in Medicine at and Associate Professor of Medicine at HMS, PG Richardson is the Clinical Director of the JLMMC at the DFCI, and KC Anderson is the Director of the JLMMC, all in Boston, MA, USA.,

    Nikhil C Munshi, Constantine S Mitsiades, Paul G Richardson & Kenneth C Anderson

Authors
  1. Nikhil C Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constantine S Mitsiades
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul G Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth C Anderson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Munshi, N., Mitsiades, C., Richardson, P. et al. Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. Nat Rev Clin Oncol 4, 394–395 (2007). https://doi.org/10.1038/ncponc0847

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0847

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing